Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2024-05-07 Regulatory Filings
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (?FS) for the design of clinical studies and the treatment choice for amy
Regulatory Filings Classification · 1% confidence The document is a press release dated May 07, 2024, from AB Science SA announcing the publication of an article in the medical journal *Muscle & Nerve* that validates a clinical trial design parameter (ΔFS) relevant to their drug masitinib. This is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is an announcement about external scientific validation and its relevance to the company's ongoing development programs. Since it is an announcement regarding scientific/clinical progress and its implications, it fits best under the general category of Investor Relations material, but specifically, it is a press release detailing corporate news that doesn't fit the other specific categories (like DIV, CAP, MANG, etc.). Given the options, this type of corporate news release, which is not a financial report, management change, or transaction notice, is often classified as a general Regulatory Filing (RNS) if a more specific category like 'Investor Presentation' (IP) or 'Management Report' (MDA) is inappropriate. However, since it is a formal announcement of a significant corporate event (publication validation), and it is not a financial report, it is most closely aligned with a general regulatory announcement or news release. Given the context of financial reporting databases, this is a standard corporate press release. It is not a proxy statement (PSI), director dealing (DIRS), or capital change (CAP). It is a general corporate update. The closest fit among the provided options for a general, non-financial, non-management-change announcement is RNS (Regulatory Filings - general regulatory announcements and fallback category).
2024-05-07 English
AB Science : La Cour d’Appel de Paris confirme la mise hors de cause du Président Directeur Général d’AB Science, Alain Moussy, et diminue le montant de la sanction imposée à AB Science
Legal Proceedings Report Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and details the outcome of an appeal concerning a regulatory decision by the AMF (Autorité des Marchés Financiers) regarding insider trading and communication obligations. It announces a legal/regulatory development affecting the company and its CEO. This type of announcement, which reports on significant legal proceedings or regulatory actions, fits best under the Legal Proceedings Report (LTR) category. It is not a full financial report (10-K, IR), an earnings release (ER), or a general regulatory filing (RNS), as it specifically addresses a legal matter's resolution.
2024-05-02 French
AB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science
Legal Proceedings Report Classification · 1% confidence The document is a press release dated May 2, 2024, detailing the outcome of an appeal to the Paris Court of Appeal regarding a decision by the French market regulator (AMF). It specifically discusses the confirmation of an acquittal for the CEO and a reduction in a financial penalty imposed on the company AB Science. This content relates directly to significant legal and regulatory actions involving the company. Among the provided categories, 'Legal Proceedings Report' (LTR) is the most appropriate fit for updates on significant lawsuits or regulatory actions. It is not an earnings release (ER), an annual report (10-K), or a general regulatory filing (RNS), as it addresses a specific legal outcome.
2024-05-02 English
AB Science annonce un léger décalage de la publication de son rapport financier annuel 2023
Report Publication Announcement Classification · 1% confidence The document is a short announcement (3699 characters) dated April 30, 2024, stating that AB Science is delaying the publication of its 'rapport financier annuel 2023' (Annual Financial Report 2023) until May 15, 2024. This text is not the Annual Report itself (10-K), but rather an announcement about the timing of its release. According to Rule 2, when a document is short and announces the publication of a report, it should be classified as a Report Publication Announcement (RPA).
2024-04-30 French
AB Science announces a slight delay in the publication of its 2023 annual financial report
Report Publication Announcement Classification · 1% confidence The document is a short announcement (3329 characters) explicitly stating that the publication of the '2023 Annual Financial Report' is being postponed until May 15, 2024. This fits the definition of a 'Report Publication Announcement' (RPA) because it is an announcement about the timing/release of a report, rather than the report itself (which would typically be a 10-K or IR). The content focuses entirely on the delay and the new publication date, aligning perfectly with the RPA definition: 'Announcement regarding the timing, release, or publication of company reports (often stating the report is attached or available on the website).'
2024-04-30 English
AB Science annonce que Santé Canada a jugé admissible la demande de réexamen du masitinib dans SLA
Legal Proceedings Report Classification · 1% confidence The document is a press release dated April 3, 2024, announcing that Health Canada has deemed AB Science's request for a re-examination of Masitinib for ALS admissible. It details the regulatory process, scientific arguments regarding data imputation, and includes quotes from an expert. This type of announcement, which communicates a specific regulatory or legal development concerning a drug or legal matter, fits best under the 'Legal Proceedings Report' (LTR) category, as it discusses a regulatory decision and the subsequent appeal/re-examination process related to drug approval, which often involves legal or quasi-legal review steps. It is not a full financial report (10-K, IR), an earnings release (ER), or a general regulatory filing (RNS), but a specific update on a significant legal/regulatory hurdle for product approval.
2024-04-03 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.